NCT04316585View on ClinicalTrials.gov

A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

September 28, 2020

Primary Completion Date

September 13, 2021

Study Completion Date

October 12, 2021

Conditions
Psoriasis
Interventions
DRUG

GSK2982772

GSK2982772 will be available as MR tablet at a unit dose strength of 480 mg.

DRUG

Placebo

GSK2982772 matching placebo tablets will be administered via the oral route.

Trial Locations (9)

T5K 1X3

GSK Investigational Site, Edmonton

T6G 1C3

GSK Investigational Site, Edmonton

V3R 6A7

GSK Investigational Site, Surrey

B2N 1L2

GSK Investigational Site, Truro

N6H 5L5

GSK Investigational Site, London

L6J 7W5

GSK Investigational Site, Oakville

K9J 5K2

GSK Investigational Site, Peterborough

G1N 4V3

GSK Investigational Site, Québec

90-265

GSK Investigational Site, Lodz

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY